WVE Wave Life Sciences Ltd.

7.47
-0.09  -1%
Previous Close 7.56
Open 7.45
Price To Book 2.23
Market Cap 256,144,433
Shares 34,289,750
Volume 194,534
Short Ratio
Av. Daily Volume 1,081,586
Stock charts supplied by TradingView

NewsSee all news

  1. Wave Life Sciences Announces Topline Data and Addition of Higher Dose Cohort in Ongoing Phase 1b/2a PRECISION-HD2 Trial in Huntington's Disease

    WVE-120102 demonstrates statistically significant reduction in disease-causing mutant HTT protein in CSF vs. placebo No difference in total HTT protein or neurofilament light chain in treated patients vs. placebo

  2. Wave Life Sciences Announces Discontinuation of Suvodirsen Development for Duchenne Muscular Dystrophy

    No change from baseline in dystrophin observed in Phase 1 open-label extension study Wave to host investor conference call at 8:00 a.m. ET today CAMBRIDGE, Mass., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences

  3. Wave Life Sciences Reports Third Quarter 2019 Financial Results and Provides Business Update

    Fast Track designation for suvodirsen received from the U.S. FDA Interim analysis of dystrophin expression from suvodirsen open-label extension study expected in 4Q 2019 Topline data from PRECISION-HD2 clinical trial

  4. Wave Life Sciences Announces Fast Track Designation from U.S. FDA for Suvodirsen

    Suvodirsen is an investigational stereopure oligonucleotide in development for the treatment of DMD patients amenable to exon 51 skipping Clinical dystrophin data from interim analysis of ongoing OLE study on track for

  5. Wave Life Sciences to Host Analyst and Investor Research Day on October 7, 2019

    CAMBRIDGE, Mass., Sept. 06, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1b/2a top line data 2H 2020.
WVE-120101
Huntington’s disease
Phase 1b/2a top line data released December 30, 2019 noted statistically significant reduction of 12.4% (p<0.05) in mutant huntingtin (mHTT) protein but no difference in total HTT (tHTT) protein and lower than competition.
WVE-120102
Huntington’s disease
Phase 2/3 trial initiation announced June 2019.
Suvodirsen (WVE-210201) - DYSTANCE 51
Duchenne muscular dystrophy - Exon 51
Phase 1 development to be discontinued following interim analysis - December 16, 2019.
Suvodirsen (WVE-210201)
DMD Exon 51

Latest News

  1. Wave Life Sciences Announces Topline Data and Addition of Higher Dose Cohort in Ongoing Phase 1b/2a PRECISION-HD2 Trial in Huntington's Disease

    WVE-120102 demonstrates statistically significant reduction in disease-causing mutant HTT protein in CSF vs. placebo No difference in total HTT protein or neurofilament light chain in treated patients vs. placebo

  2. Wave Life Sciences Announces Discontinuation of Suvodirsen Development for Duchenne Muscular Dystrophy

    No change from baseline in dystrophin observed in Phase 1 open-label extension study Wave to host investor conference call at 8:00 a.m. ET today CAMBRIDGE, Mass., Dec. 16, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences

  3. Wave Life Sciences Reports Third Quarter 2019 Financial Results and Provides Business Update

    Fast Track designation for suvodirsen received from the U.S. FDA Interim analysis of dystrophin expression from suvodirsen open-label extension study expected in 4Q 2019 Topline data from PRECISION-HD2 clinical trial

  4. Wave Life Sciences Announces Fast Track Designation from U.S. FDA for Suvodirsen

    Suvodirsen is an investigational stereopure oligonucleotide in development for the treatment of DMD patients amenable to exon 51 skipping Clinical dystrophin data from interim analysis of ongoing OLE study on track for

  5. Wave Life Sciences to Host Analyst and Investor Research Day on October 7, 2019

    CAMBRIDGE, Mass., Sept. 06, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating

  6. Wave Life Sciences Expands Board of Directors with Three New Appointments

    CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating

  7. Wave Life Sciences to Present at the Morgan Stanley Global Healthcare Conference

    CAMBRIDGE, Mass., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating